key: cord-1011822-9vp1lm89
authors: Whittaker, R.; Greve-Isdahl, M.; Boas, H.; Suren, P.; Buanes, E.; Veneti, L.
title: Severe outcomes in unvaccinated COVID-19 cases <18 years during different variant waves in Norway
date: 2022-03-30
journal: nan
DOI: 10.1101/2022.03.29.22273093
sha: f9aeb447ce9a47b6f324e78b844defe0686d1588
doc_id: 1011822
cord_uid: 9vp1lm89

Objectives We used linked individual-level data from national registries to compare the risk of severe outcomes among unvaccinated COVID-19 cases <18 years between waves of the SARS-CoV-2 Alpha, Delta and Omicron variants in Norway. Methods Our outcomes were hospitalisation with acute COVID-19 or multisystem inflammatory syndrome in children (MIS-C). We calculated adjusted risk ratios (aRR) with 95% confidence intervals (CIs) using multivariable log-binomial regression, adjusting for variant wave, demographic characteristics and underlying comorbidities. Results We included 10,538 Alpha (21 hospitalised with acute COVID-19, 7 MIS-C), 42,362 Delta (28 acute COVID-19, 14 MIS-C) and 82,907 Omicron wave cases (48 acute COVID-19, 7 MIS-C). The risk of hospitalisation with acute COVID-19 in cases <1 year was lower in the Delta (aRR: 0.28, 95% CI: 0.16-0.89) and Omicron wave (aRR: 0.41, 95% CI: 0.20-0.81), compared to the Alpha wave. We found no difference in the risk for this outcome for Omicron compared to Delta in any age group. The risk of MIS-C was lower in the Omicron wave compared to the Alpha (aRR: 0.09, 95% CI: 0.03-0.27) and Delta wave (aRR: 0.26, 95% CI: 0.10-0.63). Conclusions We found no evidence of a difference in the risk of hospitalisation due to acute COVID-19 among unvaccinated cases <18 years for Omicron compared to Delta, but a reduced risk among cases <1 year in Omicron and Delta waves, compared to Alpha. Results also suggest a decrease in the risk of MIS-C in the Omicron wave compared to the Alpha and Delta waves.

We compare the risk of severe outcomes in unvaccinated COVID-19 cases <18 years between 4 0 waves of the SARS-CoV-2 Alpha, Delta and Omicron variant in Norway. 4 1 4 2 What's Known on This Subject 4 3 Currently, limited evidence suggests no clear difference in the risk of severe disease outcomes 4 4 among children infected with different SARS-CoV-2 variants. The risk of multisystem 4 5 inflammatory syndrome in children following infection with the Omicron variant has not been 4 6 quantified. 4 7 4 8 What This Study Adds 4 9 We find a lower risk of hospitalisation due to acute COVID-19 among cases <1 year in the 5 0 Delta and Omicron waves compared to the Alpha wave, and a lower risk of multisystem 5 1 inflammatory syndrome in the Omicron wave, in Norway. 5 2 5 3 Word count: 2,990 5 4 Introduction Since the beginning of 2021, Norway has experienced three waves of COVID-19 cases when 1 1 6 different VOC were dominant; Alpha (pangolin designation B.1.1.7) (4), Delta (21) and 1 1 7 Omicron (8) . We used linked individual-level data from national registries to compare the risk 1 1 8 of severe outcomes among unvaccinated COVID-19 cases <18 years between these three 1 1 9 variant waves. Study setting 1 2 2 Norway (population 5.4 million, of whom 1.1 million <18 years) has had a broad testing 1 2 3 strategy for COVID-19 in children since autumn 2020. Four pillars of the national pandemic 1 2 4 response have been testing, isolation, contact tracing and quarantine. Through this framework 1 2 5 SARS-CoV-2 tests have been available free of charge for everyone, including those with mild 1 2 6 or no symptoms, close contacts and individuals in quarantine. Routine bi-weekly screening of 1 2 7 school children with rapid antigen tests in areas with high transmission was undertaken for 1 2 8 secondary school students from late-August 2021 and for primary school students from 1 2 9 November 2021 until January 2022. Positive rapid antigen tests were confirmed with PCR. August 2021 there has been a general recommendation that all pregnant women in the second 1 3 3 or third trimester get vaccinated. For women with underlying risk factors, vaccination was 1 3 4 recommended in the first trimester (22) . Data sources and study design 1 3 6 We obtained data through the Norwegian national preparedness registry for COVID-19 (23) . The preparedness registry contains individual-level data from different central health 1 3 8 registries, national clinical registries, and other national administrative registries. It covers all 1 3 9 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 30, 2022. ;  residents in Norway, and includes data on all laboratory-confirmed cases of COVID-19 in 1 4 0 Norway and all hospitalisations, intensive care admissions and deaths among cases. Further We conducted a cohort study, including reported cases of COVID-19 aged <18 years who 1 4 4 tested positive from 15 March 2021 up to 30 January 2022, were unvaccinated at date of 1 4 5 positive test and had also not previously been diagnosed with COVID-19, and had a national Definition of variant waves 1 4 9 The national laboratory database houses data on SARS-CoV-2 test results from all Norwegian of SARS-CoV-2 in Norway has been described in further detail elsewhere (24). Using data 1 5 4 from the national laboratory database we identified different variant waves based on date of 1 5 5 positive test. The distribution of different variants among cases <18 years over time in 1 5 6 Norway is presented in Figure 1 , with the underlying data available in supplement B. We wave as week 2-4 (10-30 January) 2022. In the Omicron wave, sublineage BA.1 was Severity outcome definitions 1 6 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 30, 2022. ;  Our severity outcomes of interest were: 1) admission to hospital with acute COVID-19 Classification of Diseases-10 diagnosis code U10.9. Clinical criteria for the diagnosis of MIS- Data analysis 1 7 0 We described cases by variant wave, severity outcome, demographic characteristics and underlying comorbidities. We also described other outcomes among hospitalised patients 1 7 2 including length of stay (LoS) in hospital and admission to an intensive care unit (ICU), as 1 7 3 well as all deaths in the study cohort. For our three severity outcomes, we calculated adjusted 1 7 4 risk ratios (aRR) with 95% confidence intervals (CIs) using multivariable log-binomial 1 7 5 regression. Explanatory variables to analyse differences in our outcomes included variant 1 7 6 wave (Alpha, Delta or Omicron), age (as continuous or categorical variable), sex, country of 1 7 7 birth, region of residence, and underlying comorbidities. The categorisation of explanatory 1 7 8 variables is presented in Table 1 and further detailed in Supplement A, section 2. Explanatory 1 7 9 variables were first checked in univariable models, and those with p<0.2 were further 1 8 0 explored in multivariable models. Explanatory variables were further categorised in some 1 8 1 models to best fit the data, for example a dichotomous variable for underlying comorbidities 1 8 2 (yes/no). We maintained the variant wave variable in each multivariable analysis, even if not 1 8 3 significant. We used Akaike Information Criteria and the likelihood ratio test to check model 1 8 4 fit. We ran models for each variant combination (Delta vs. Alpha, Omicron vs. Alpha, 1 8 5 Omicron vs. Delta) for all cases <18 years, as well as for the age subgroups <1, 1-11 and 12- 17 years. For the age group 12-17 years, we also conducted a sensitivity analysis, including

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ;  vaccinated cases and reinfections, and adjusting for vaccination status (supplement A, section 1 8 8 3). Further, we validated the variant wave variable by running models for all COVID-19 cases 1 8 9 reported in Norway, and comparing results to estimates based on cases with known variant 1 9 0 (supplement A, section 4). Statistical analysis was performed in Stata version 16 (Stata Corporation, College Station, Texas, US). Ethical approval for studies on the risk of severe disease by SARS-CoV-2 variant based on 1 9 4 data from the national preparedness registry for COVID-19 was granted by Regional Committees for Medical Research Ethics -South East Norway, reference number 249509. Study cohort 1 9 8 The total number of reported cases of COVID-19 aged <18 years was 10,620 during the 1 9 9 Alpha wave, 53,724 during the Delta wave and 133,383 during the Omicron wave. Of these, characteristics of the study cohort by variant are presented in Table 1 . admissions >14 days after positive test were observed (Table 1) . Of the 97, 48 (50%) were <1 2 0 9

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ;

1 0

year of age, 44 (45%) were female and 83 (86%) had no registered comorbidity. Of the 48 <1 year, 32 (67%) were <3 months of age, and 42 (88%) were <6 months of age. In the Alpha, Delta and Omicron waves, 21 (0.2%), 28 (0.07%) and 48 (0.06%) cases <18 (Table 1, Table 2 ). The risk of hospitalisation with acute COVID-19 as main year (aRR Delta compared to Alpha: 0.28, 95% CI: 0.16-0.89; aRR Omicron compared to did not observe any difference in the adjusted risk in any age group in the Omicron wave as main cause of hospitalisation, although we did observe a decreased risk in cases <18 years 2 2 3 in the Omicron wave compared to Delta wave (aRR: 0.67, 95% CI: 0.48-0.94) ( Table 2 ). Twenty-eight cases of MIS-C were reported across the three waves (0.02% of all cases) 2 2 6 ( Table 2 ). The median age was 6.5 years (interquartile range (IQR): 4-9.5; range 1-17), 12 2 2 7 (43%) were female and 26 (93%) had no registered comorbidity. In the Alpha, Delta and Omicron waves, 7 (0.07%), 14 (0.03%) and 7 (0.008%) cases <18 years were diagnosed with MIS-C, respectively (Table 1, Table 2 ). We did not observe a significant difference in the risk . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 1 Length of hospital stay, admission to intensive care and death 2 3 4 The median LoS among cases hospitalised with acute COVID-19 as main cause was 0.8 days (interquartile range (IQR): 2-6). Data on LoS is not presented by wave for MIS-C cases due 2 3 8 to the small number of MIS-C cases in each wave. Across all three waves, 6 (6%) cases hospitalised with acute COVID-19 as main cause and 4 (14%) MIS-C cases were admitted to 2 4 0 ICU. This equates to 0.007% of reported cases being admitted to ICU for either acute We find no clear evidence of a difference in the risk of hospitalisation due to acute COVID- 19 among cases <18 years in the Omicron wave compared to the Delta wave. Our results are 2 4 7 in line with similar national studies from both England (5) and Denmark (12) . The study in 2 4 8 England, which included over 300,000 COVID-19 cases and 1,500 hospitalisations <20 years, 2 4 9 did suggest a potentially small decrease in the risk of hospitalisation for Omicron compared to 0.78, 95% CI: 0.60-1.00). We did find a lower risk for hospitalisation regardless of main indicator should be interpreted with caution as it will include patients admitted for non- COVID-19 related causes. We find no difference in the risk of hospitalisation with COVID- 19 as main cause in the Omicron wave compared to the Delta wave. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022 . ;

The risk of hospitalisation with acute COVID-19 among cases <1 year was lower in the Delta 2 5 7 and Omicron waves, compared to the Alpha wave. As the majority of hospitalised cases <1 2 5 8 year across the three waves were <3 months old, the decrease in risk may be related to 2 5 9 protection offered to infants born to mothers vaccinated during pregnancy (27). Vaccination wave. Conversely, we did not a see a difference in the risk of hospitalisation with acute Omicron wave (7). Compared to other VOC, the Omicron variant has been shown to replicate more easily in the 2 6 6 upper respiratory tract but less well in the lungs (28) . In this study we could not explore 2 6 7 whether the clinical presentation of children hospitalised with Omicron had changed, and management of paediatric patients as Omicron circulates. Previous studies from the USA and Denmark estimated the incidence of MIS-C (defined (29, 30). A subsequent study from Denmark found that this risk did not change among unvaccinated cases during a wave of Delta infections (20). We find that the incidence of MIS- Delta wave was approximately 1 in 3,000 cases who were unvaccinated and had not been Omicron waves. Also, the small number of outcomes must be considered, which restricted 3 0 7 further exploration of our results. Given the low incidence of severe outcomes among child 34, 36), analyses of pooled data from several countries or meta-analyses could provide more 3 1 0 precise estimates that can better elucidate differences in the risk of these outcomes between Further studies are still needed to establish differences in disease severity between different 3 1 7

Omicron sublineages. We found no evidence of a difference in the risk of hospitalisation due to acute COVID-19 3 2 0 among unvaccinated cases <18 years for Omicron compared to Delta in Norway, but a First and foremost, we wish to thank all those who have helped establish and/or report data 3 2 6 housed in the national emergency preparedness registry for COVID-19 at the Norwegian

Institute of Public Health. We would also like to specifically thank Trude Lyngstad, Jostein 3 2 8 Starrfelt, Elina Seppälä, Mari Grøsland and 'Team Riskgroup' at the Norwegian Institute of 3 2 9 Public Health for their assistance in the cleaning of the data from the different registries, and 3 3 0 additionally Trude Lyngstad for her assistance in the production of Figure S1 . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

World Health Organisation. Tracking SARS-CoV-2 variants

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at

SARS-CoV-2 Omicron VOC Transmission in Danish Households. Medrxiv. 2022

Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant

World Health Organisation. COVID-19 Weekly Epidemiological Update, Edition 81

Sick-Samuels AC. Acute covid-19 and multisystem inflammatory syndrome in children

Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: A systematic review and individual patient meta-analysis

Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study

Acute upper airway disease in children with the omicron (B.1.1.529) variant of SARS-CoV2: a report from the National COVID Cohort Collaborative (N3C). Medrxiv. 2022

Croup during the COVID-19 Omicron Variant Surge

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario

Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative

Evaluation of childhood hospitalization rates and degree of severity of SARS-CoV-2 variants, including B.1.1.7 (Alpha), B.1.315/P.1 (Beta/Gamma), and B.1.617.2 (Delta)

Comparison of the clinical characteristics and outcomes of COVID-19 in children before and after the emergence of Delta variant of concern in Japan

Multisystem Inflammatory Syndrome in Children Following the SARS-CoV-2 Delta Variant in Denmark: Clinical Phenotype and Risk by Vaccination Status and Compared to the Pre-Delta COVID-19 Era

No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway

Coronavirus vaccine -information for the public

Norwegian Institute of Public Health. Påvisning og overvåkning av SARS-CoV-2-virusvarianter

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months -17 States

Omicron variant replication in human bronchus and lung ex vivo

Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2

Multisystem inflammatory syndrome in children occurred in one of four thousand children with severe acute respiratory syndrome coronavirus 2

Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years -United States

Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged

10 States

 3 3 2 3 3 3 variant (bars, left y-axis), and proportion of cases with known variant that were the Alpha, 3 3 4 Delta or Omicron variant of concern (lines, right y-axis), by week, 1 January 2021 -6 3 3 5 February 2022. 3 3 6 The data behind the figure are available in supplement B. During the Alpha wave (week 11- 3 3 7 20 2021), the proportion of cases that were known to be infected with Alpha ranged from 3 3 8 86%-95% of cases with known variant, however, the vast majority of other cases with known 3 3 9 variant were reported as 'probable variant of concern'. In Norway, there was minimal 3 4 0 circulation of other defined variants of concern (Beta, B.1.351 and Gamma, P.1), thus is it is 3 4 1 reasonable to assume that most cases reported as 'probable variant of concern' were also the 3 4 2 Alpha variant. Taking these cases into account the proportion infected with Alpha among 3 4 3 those with known variant ranges from 94%-100% in the Alpha wave.